TBI-1401(HF10)

BIOLOGICAL3 trials

Sponsors

Takara Bio Inc.

Conditions

Melanoma Stage IIIMelanoma Stage IVPancreatic Cancer Stage IIIPancreatic Cancer Stage IVSolid Tumor

Phase 1

A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial Lesions

CompletedNCT02428036

Takara Bio Inc.Solid Tumor

Start: 2015-06-30End: 2017-06-30Updated: 2017-07-02

Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.

Active, not recruitingNCT03252808

Takara Bio Inc.Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV

Start: 2017-09-25End: 2035-03-31Target: 36Updated: 2024-12-09

Phase 2

A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma

CompletedNCT03153085

Takara Bio Inc.Melanoma Stage III, Melanoma Stage IV

Start: 2017-05-25End: 2018-12-14Updated: 2024-12-09

Related Papers

Immunological impact of canerpaturev (C-REV, formerly HF10), an oncolytic viral immunotherapy, with or without ipilimumab (Ipi) for advanced solid tumor patients (pts).

Journal of Clinical Oncology2019-05-206 citations

Results from phase I study of the oncolytic viral immunotherapy agent canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer.

Journal of Clinical Oncology2019-01-297 citations

Topline results from phase II of combination treatment with canerpaturev (HF10), an oncolytic viral immunotherapy, and ipilimumab in patients with unresectable or metastatic melanoma after anti-PD-1 therapy

Annals of Oncology2018-10-014 citations